Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets collapse
Tue, 2 Jun 01:30 pm

After opening the day in red, the Indian share markets extended their losses in the post-noon trading session. Most sectoral indices are trading in red with FMCG and Auto sectors bearing the maximum burnt.

The BSE-Sensex is down 421 points (1.5%) and NSE-Nifty is trading 134 points down (1.6%). The S&P BSE Midcap and S&P BSE Smallcap indices are both trading on a negative note by 1.3%. Gold prices, per 10 grams, are trading at Rs 26,766 levels. Silver price, per kilogram, is trading at Rs 38,261 levels. Crude oil is trading at Rs 3,882 per barrel. The rupee is trading at 63.79 to the US dollar.

Reserve Bank Governor Raghuram Rajan has announced the second bi-monthly monetary policy statement. The Reserve Bank of India (RBI) has cut the repo rate by 25 basis points (bps) to 7.25%. This takes the total reduction in interest rate to 75 bps in the current year after the previous cuts in January and March. This move was widely anticipated given the RBI's comfort with consumer price inflation and the marked slowdown in industrial growth. However, both CRR (cash reserve ratio) and SLR (statutory liquidity ratio) rates have been left unchanged. It should also be noted that according to the RBI Credit Policy, the inflation is expected to rise to 6% by January 2016.

Stocks in the Pharma sector are trading mixed today with Orchid Chemicals and Cipla leading the losses. As per a leading financial daily, Aurobindo Pharma Ltd has received final approvals from the US Food & Drug Administration (US FDA) to manufacture and market Metronidazole tablets. These Metronidazole tablets of 250 mg and 500 mg dosages are used to treat different types of infections which are due to particular types of bacteria and some other infectious organisms. As the company stated, it will commence shipping of the product shortly. The market size of the product is estimated at US$58 million for the twelve months ending March 2015 according to the IMS (Intercontinental Marketing Services) data. Currently the stock of Aurobindo Pharma is trading up by 0.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets collapse". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.